American Journal on Addictions · 2020 · 97 citations · 15 references
MedicinePharmacologyClinical PharmacologyPsychopharmacologySubstance Use DisordersAddictionDrug DependenceOpioid AnalgesicsOpioid PharmacologySubstance WithdrawalBuprenorphine TreatmentIllicit Fentanyl UsePharmacological Management Of Withdrawal
BACKGROUND AND OBJECTIVES: Individuals exposed to fentanyl are at risk of precipitated withdrawal using typical buprenorphine/naloxone induction procedures. METHODS: This case series describes buprenorphine/naloxone inductions of four individuals who tested positive for fentanyl. RESULTS: Buprenorphine-precipitated withdrawal was observed in two individuals who completed a conventional buprenorphine/naloxone induction strategy. Two more individuals completed a revised buprenorphine/naloxone induction strategy that did not precipitate withdrawal. DISCUSSION AND CONCLUSION: Using multiple 2 mg doses of buprenorphine/naloxone in patients already in mild/moderate withdrawal improved outcomes. SCIENTIFIC SIGNIFICANCE: Persons who use illicit fentanyl might be less likely to experience precipitated withdrawal from this revised buprenorphine/naloxone induction strategy. (Am J Addict 2021;30:83-87).
15
Marc Vogel, Robert Hämmig, Antje Kemter et al. · Substance Abuse and Rehabilitation · 2016 · 216 citations · Full text
CLINICAL ACTIONS OF FENTANYL AND BUPRENORPHINE
R Boas, J.W. Villiger · British Journal of Anaesthesia · 1985 · 214 citations · Full text
D. Andrew Tompkins, George E. Bigelow, Joseph A. Harrison et al. · Drug and Alcohol Dependence · 2009 · 177 citations · Full text